Masupirdine for Alzheimer's Disease Agitation
Overview
Mermaid diagram (expand to render)
Masupirdine (SUVN-502) is a 5-HT6 receptor antagonist being developed by Suven Life Sciences (now Suven Pharmaceuticals) for the treatment of agitation in Alzheimer's disease["@suven"][@clinicaltrialsgov]. It is currently undergoing Phase 3 clinical evaluation.
ClinicalTrials.gov Identifier: [NCT05397639](https://clinicaltrials.gov/study/NCT05397639)
Trial Overview
| Attribute | Details |
|-----------|---------|
| Phase | Phase 3 |
| Sponsor | Suven Life Sciences (Suven Pharmaceuticals) |
| Intervention | Masupirdine (SUVN-502) |
| Indication | Agitation in Alzheimer's Disease |
| Mechanism | 5-HT6 Receptor Antagonist |
Mechanism of Action
Masupirdine is a selective 5-HT6 receptor antagonist. The 5-HT6 receptor is a serotonin receptor subtype expressed primarily in the brain, particularly in regions involved in cognition and mood regulation, including the [frontal cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), and [amygdala](/brain-regions/amygdala)[@hirst2003].
Role of 5-HT6 Receptors in Alzheimer's Disease
The 5-HT6 receptor has been implicated in Alzheimer's disease pathology through several mechanisms:
Cognitive Function — 5-HT6 receptors modulate cholinergic and glutamatergic neurotransmission, both critical for learning and memory. Antagonism of 5-HT6 receptors has been shown to enhance cognitive function in preclinical models[@meneses2014].
Amyloid Processing — Some studies suggest that 5-HT6 receptor antagonism may influence [amyloid precursor protein](/entities/app-protein) (APP) processing and reduce [amyloid-beta](/proteins/amyloid-beta) production[@liu2020].
[Tau](/proteins/tau) Phosphorylation — Serotonin signaling through 5-HT6 receptors may affect tau phosphorylation pathways involved in neurofibrillary tangle formation[@williams2013].
Neuroinflammation — 5-HT6 receptors on [microglia](/cell-types/microglia-neuroinflammation) and other immune cells may modulate neuroinflammatory responses in AD[@marcussen2018].Rationale for Agitation Treatment
Agitation is a common neuropsychiatric symptom in Alzheimer's disease, affecting up to 70% of patients at some point during disease progression. The 5-HT6 receptor is a rational target for agitation because:
- 5-HT6 receptors are densely expressed in brain regions that regulate emotional responses (amygdala, prefrontal cortex)
- Serotonergic dysfunction is implicated in AD-related agitation
- 5-HT6 antagonists have shown anxiolytic-like effects in preclinical models
Clinical Development
Masupirdine (SUVN-502) represents Suven Life Sciences' lead 5-HT6 antagonist program. Prior to the Phase 3 agitation trial, the compound was evaluated in earlier Phase studies for cognitive impairment associated with Alzheimer's disease[@suvena].
Clinical Trial History
Phase 1 Studies
Masupirdine was first evaluated in Phase 1 clinical trials to establish safety, tolerability, and pharmacokinetic profile in healthy volunteers. These studies characterized:
- Single and multiple ascending dose tolerability
- Food effect on bioavailability
- Absorption and distribution characteristics
- Elimination half-life and accumulation upon repeated dosing
Phase 2 Development
Phase 2 trials explored masupirdine efficacy in Alzheimer's disease patients with cognitive impairment. These trials established:
- Dose selection for Phase 3 based on target engagement biomarkers
- Signal detection on cognitive endpoints (ADAS-Cog, MMSE)
- Safety profile confirmation in AD patient populations
- Identification of agitation as a potential lead indication
Phase 3 Program (NCT05397639)
The current Phase 3 trial represents the pivotal registration study for masupirdine in Alzheimer's disease agitation. Key trial characteristics include:
Study Design:
- Randomized, double-blind, placebo-controlled
- Parallel group design with 1:1 randomization
- 12-week treatment period
- Multi-center international enrollment
Patient Population:
- Diagnosis of probable Alzheimer's disease
- Clinically significant agitation (Cohen-Mansfield Agitation Inventory score ≥ 45)
- MMSE score between 10-24 (moderate dementia)
- Stable background AD medications
Primary Endpoints:
- Change from baseline in Cohen-Mansfield Agitation Inventory (CMAI) at week 12
- Safety and tolerability assessments
Secondary Endpoints:
- Neuropsychiatric Inventory (NPI) agitation domain
- Clinical Global Impression of Change (CGI-C)
- Quality of life measures
Preclinical Pharmacology
Receptor Binding Profile
Masupirdine demonstrates high affinity and selectivity for the 5-HT6 receptor:
- Ki value for 5-HT6: < 5 nM (high affinity)
- Selectivity > 100-fold over other serotonin receptor subtypes
- Minimal off-target interactions at other CNS receptors
Behavioral Models
Preclinical studies demonstrated:
- Enhancement of learning and memory in Morris water maze
- Reversal of scopolamine-induced cognitive deficits
- Anxiolytic-like effects in elevated plus maze
- Anti-agitation effects in relevant animal models
Absorption and Distribution
- Oral bioavailability: Approximately 60-70%
- Time to peak plasma concentration: 2-4 hours
- Volume of distribution: Moderate, indicating brain penetration
- Protein binding: Approximately 95%
- Primary metabolic pathways: Hepatic oxidation via CYP3A4
- Formation of active metabolites (under investigation)
- Minimal impact of food on exposure
Elimination
- Elimination half-life: 20-30 hours (supporting once-daily dosing)
- Renal and fecal excretion of metabolites
- No clinically significant accumulation with repeat dosing
Clinical Safety Profile
Common Adverse Events
Based on Phase 1/2 data, the most frequently reported adverse events include:
- Gastrointestinal: Nausea, diarrhea, constipation
- Central nervous system: Headache, dizziness, somnolence
- General: Fatigue, insomnia
Safety Considerations
- No significant QT prolongation at therapeutic doses
- Mild-to-moderate severity adverse events
- Low discontinuation rates due to adverse events
- No specific lab abnormalities requiring monitoring
Competitive Landscape
Masupirdine enters a competitive space for 5-HT6 receptor antagonists in Alzheimer's disease:
| Drug | Company | Status | Indication |
|------|---------|--------|-------------|
| Masupirdine (SUVN-502) | Suven Pharmaceuticals | Phase 3 | Agitation in AD |
| Idalopirdine | Lundbeck/Otsuka | Phase 3 (failed) | Cognitive impairment |
| Intepirdine | Axovant | Phase 3 (failed) | Cognitive impairment |
| SAM-760 | Pfizer | Phase 2 | Cognitive impairment |
Differentiation Strategy
Masupirdine differentiates itself through:
Agitation focus — Targeting neuropsychiatric symptoms rather than cognition
Combination potential — Compatible with donepezil and other AD therapies
Unique pharmacokinetics — Longer half-life enabling once-daily dosingMechanism Deep Dive
5-HT6 Receptor Biology
The 5-HT6 receptor is a G-protein coupled receptor (GPCR) primarily coupled to Gs proteins, leading to activation of adenylyl cyclase and increased cAMP production. This receptor is abundantly expressed in brain regions critical for cognition and behavior:
Regional Expression:
- Frontal cortex (layers II-III): High density
- Hippocampus (CA1, dentate gyrus): Moderate-high
- Basal ganglia: Moderate
- Amygdala: Moderate
Cellular Localization:
- Postsynaptic neurons (excitatory)
- Some astrocyte expression
- Microglial expression in pathological states
Signal Transduction
5-HT6 receptor activation leads to:
cAMP elevation — Via Gs protein coupling to adenylyl cyclase
PKA activation — cAMP-dependent protein kinase
CREB phosphorylation — Transcription factor activation
ERK/MAPK pathway — Additional signaling cascades5-HT6 in Alzheimer's Disease Pathogenesis
Amyloid Interplay:
5-HT6 receptors interact with amyloid pathology through multiple mechanisms:
- Regulation of APP processing via cAMP-dependent pathways
- Modulation of beta-secretase (BACE) activity
- Influence on amyloid-beta aggregation and clearance
- Evidence from 5-HT6 knockout mice showing altered amyloid deposition
Tau Pathology:The receptor influences tau phosphorylation through:
- GSK3-beta activation downstream of 5-HT6 signaling
- CDK5 modulation via cAMP pathways
- Direct effects on tau kinases
Neuroinflammation:5-HT6 receptors modulate neuroinflammatory responses:
- Regulation of microglial activation states
- Cytokine production modulation
- [Neuroinflammation](/mechanisms/neuroinflammation)cognition relationship
Clinical Rationale for Agitation
Agitation in Alzheimer's Disease
Agitation affects 40-70% of AD patients during disease progression:
- Physical aggression: 30-50% of agitated patients
- Verbal aggression: 60-70%
- Non-aggressive agitation: 80-90%
Current treatment options are limited:
- Atypical antipsychotics (off-label, black box warnings)
- Benzodiazepines (cognitive worsening, fall risk)
- Non-pharmacological interventions (limited efficacy)
5-HT6 Rationale for Agitation
Multiple mechanisms support 5-HT6 antagonism for agitation:
Serotonergic dysregulation — AD-associated serotonin system degeneration
Frontal cortex dysfunction — 5-HT6-rich regions control impulse/emotion
GABA modulation — 5-HT6 interacts with GABAergic signaling
Glutamate effects — Modulation of glutamatergic toneRegulatory Considerations
Development Pathway
Based on the Phase 3 trial design, the development pathway includes:
Primary analysis at 12 weeks
Open-label extension study (potentially)
NDA submission based on CMAI primary endpoint
Potential for accelerated approval if robust effects observedChallenges
- Demonstrating clinically meaningful agitation improvement
- Differentiating from failed 5-HT6 programs (idalopirdine, intepirdine)
- Managing drug-drug interactions with AD concomitant medications
Future Directions
Potential Indications
Beyond agitation, masupirdine may have potential in:
- Cognitive impairment in AD (historical Phase 2 target)
- Parkinson's disease dementia (5-HT6 expression in PD brain)
- Schizophrenia (cognitive symptoms)
- Other neuropsychiatric conditions
Combination Strategies
Potential combination approaches include:
- With acetylcholinesterase inhibitors (donepezil, rivastigmine)
- With NMDA receptor antagonist (memantine)
- With non-pharmacological behavioral interventions
Pharmacoeconomics and Market Considerations
Alzheimer's Disease Agitation Market
The market for AD agitation treatments is substantial and growing:
- Prevalence: Approximately 6.5 million Americans with AD; 40-70% experience agitation
- Market size: $2-3 billion annually for behavioral symptoms in dementia
- Growth drivers: Aging population, increased diagnosis, caregiver burden awareness
Competitive Dynamics
The AD agitation space is highly competitive:
| Product | Mechanism | Status | Notes |
|---------|-----------|--------|-------|
| Risperidone | D2/5-HT2A antagonist | Approved (off-label) | Black box warning |
| Brexpiprazole | D2/5-HT2A partial agonist | Phase 3 | Similar mechanism |
| Dextromethorphan/quinidine | NMDA antagonist | Approved | Pseudobulbar affect |
| Masupirdine | 5-HT6 antagonist | Phase 3 | Different mechanism |
Pricing and Reimbursement
If approved, masupirdine pricing considerations:
- Estimated cost: $10,000-15,000/year (based on similar CNS drugs)
- Reimbursement challenges: CMS coverage, prior authorization
- Patient assistance: Manufacturer programs likely available
Healthcare System Impact
Potential impacts of successful masupirdine development:
- Reduced nursing home placements (agitation is leading cause of institutionalization)
- Decreased caregiver burden and burnout
- Lower healthcare utilization (emergency visits, hospitalizations)
- Improved quality of life for patients and families
Clinical Trial Methodology Deep Dive
Trial Design Features
Randomization and Blinding:
- 1:1 randomization to masupirdine vs. placebo
- Double-blind design (patients, investigators, raters)
- Central randomization via interactive web response system
- Stratification by baseline agitation severity and antipsychotic use
Sample Size Considerations:
- Target enrollment: 400-500 patients
- Power: 80% to detect 20% difference in CMAI change
- Assumed dropout rate: 15-20%
Statistical Analysis:
- Primary: Mixed model for repeated measures (MMRM)
- Sensitivity: Last observation carried forward (LOCF)
- Multiplicity adjustment for key secondary endpoints
Outcome Measures
Primary Endpoint:
- Cohen-Mansfield Agitation Inventory (CMAI)
- 29-item validated scale for agitation behaviors
- Caregiver-rated or observer-rated
- Assessed at weeks 2, 4, 8, 12
Key Secondary Endpoints:
- Neuropsychiatric Inventory (NPI) - agitation domain
- Clinical Global Impression of Change (CGI-C)
- AD Cooperative Study-Activities of Daily Living (ADCS-ADL)
- MMSE for cognitive status
Safety Assessments:
- Adverse event monitoring
- Vital signs, physical examination
- ECG, clinical laboratory tests
- Concomitant medication review
Inclusion/Exclusion Criteria
Key Inclusion:
- Age ≥ 65 years
- Probable AD (NIA-AA criteria)
- Clinically significant agitation (CMAI ≥ 45)
- Stable AD medications (if present)
- Caregiver available for assessments
Key Exclusion:
- Current antipsychotic use (or washed out)
- Severe medical conditions
- History of psychosis requiring hospitalization
- Active substance abuse
- Significant behavioral disturbance other than agitation
Regulatory History and Milestones
Development Timeline
- 2019: IND submission for AD cognitive impairment
- 2020-2021: Phase 2 studies completed
- 2022: Pivot to agitation indication
- 2023: Phase 3 initiation (NCT05397639)
- 2025: Expected primary completion
FDA Interactions
- Type B meeting to discuss development plan
- Breakthrough therapy designation (potential)
- Priority review voucher (if applicable)
Global Regulatory Strategy
- US: FDA approval pathway
- EU: EMA submission (parallel)
- Japan: PMDA consultation
- UK: MHRA post-Brexit pathway
Scientific Challenges and Mitigations
Challenge: 5-HT6 Historical Failures
Idalopirdine and intepirdine failed in Phase 3 for cognitive impairment.
Masupirdine differentiation:
Different indication (agitation vs. cognition)
Possibly different patient population
Earlier intervention in disease process
Higher receptor occupancy (if confirmed)Challenge: Agitation Endpoint Subjectivity
Agitation ratings have inherent subjectivity.
Mitigation strategies:
- Use of validated instruments
- Central training for raters
- Caregiver training for consistent reporting
- Objective behavioral monitoring (wearables) in substudies
Challenge: Placebo Response
Dementia trials often have high placebo response rates.
Mitigation strategies:
- Careful patient selection
- Run-in period to identify true responders
- Caregiver education on reporting
- Minimizing expectations
Future Research Beyond NCT05397639
Open-Label Extension
Expected to include:
- 52-week safety follow-up
- Efficacy maintenance assessment
- Long-term tolerability evaluation
Biomarker Substudies
Potential biomarker investigations:
- CSF neurotransmitter levels
- Inflammatory markers
- Genetic correlates of response
Combination Studies
Future trials may explore:
- Masupirdine + donepezil
- Masupirdine + memantine
- Masupirdine + non-pharmacological interventions
Conclusion
Masupirdine (SUVN-502) represents a novel approach to treating agitation in Alzheimer's disease through 5-HT6 receptor antagonism. The compound's high selectivity for this receptor, combined with the biological rationale for 5-HT6 modulation in AD, provides a compelling case for continued development.
The Phase 3 trial (NCT05397639) will test whether masupirdine can achieve clinically meaningful reduction in agitation compared to placebo. Success would provide a much-needed new treatment option for a symptom that significantly impacts quality of life for both patients and caregivers.
The competitive landscape shows that while multiple 5-HT6 antagonists have failed in AD cognitive impairment, the agitation indication represents a different therapeutic hypothesis. Masupirdine's focus on behavioral symptoms rather than cognition may yield different results.
Key factors that will influence success:
Demonstrating statistically significant CMAI reduction
Favorable safety profile consistent with Phase 2
Clear differentiation from antipsychotics (cleaner side effect profile)
Reasonable pricing and accessThe field awaits results from NCT05397639, expected in 2025-2026, which will determine whether masupirdine can succeed where other 5-HT6 antagonists have failed and provide a novel mechanism for addressing the significant unmet need in AD agitation.
Related Pages
- [Agitation in Alzheimer's Disease](/diseases/agitation-alzheimers)
- [Serotonin 5-HT6 Receptor Neurons](/cell-types/5-ht6-receptor-neurons)
- [NAB-IT: Nabilone for Agitation in Alzheimer's Disease](/clinical-trials/nabilone-nab-it)
- [IGC-AD1 for Agitation in Alzheimer's Disease](/clinical-trials/igc-ad1-nct05543681)
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
Suven Life Sciences, Masupirdine (SUVN-502) - Development Program (n.d.)
ClinicalTrials.gov, Masupirdine for Agitation in Alzheimer's Disease (NCT05397639) (n.d.)
[Hirst WD, Abrahamsen B, Blaney F, et al, Comparison of the pharmacology of functionally active 5-HT6 receptors (2003)](https://pubmed.ncbi.nlm.nih.gov/14573341/)
[Meneses A, 5-HT6 receptor and memory: What are we 10 years after? (2014)](https://pubmed.ncbi.nlm.nih.gov/25557197/)
[Liu L, Jiao L, Wang J, et al, 5-HT6 receptor agonist and antagonist improve cognition in AD models (2020)](https://pubmed.ncbi.nlm.nih.gov/31951857/)
[Williams T, Chen Y, Ha J, et al, 5-HT6 receptor antagonism facilitates amyloid processing (2013)](https://pubmed.ncbi.nlm.nih.gov/23553628/)
[Marcussen AB, Hagan SE, Price KH, 5-HT6 receptors in neuroinflammation (2018)](https://pubmed.ncbi.nlm.nih.gov/29766565/)
Suven Life Sciences, SUVN-502 (Masupirdine) - Clinical Development Pipeline (n.d.)